Immunization: Difference between revisions
From IDWiki
(Imported from text file) Β |
(ββ) Β |
||
(11 intermediate revisions by the same user not shown) | |||
Line 1: | Line 1: | ||
==Passive and Active== |
|||
= Vaccination = |
|||
*'''Passive''' immunization refers to the transfer of antibodies to confer protection |
|||
== Passive and Active == |
|||
**Mother-to-child transfer and immunoglobulins are examples |
|||
**Hepatitis B |
|||
**Chicken pox, that cannot recieve vaccine (in pregnant women, immunocompromised, baby exposed by mom at birth) |
|||
**Measles, that cannot recieve vaccine |
|||
**Hepatitis A, that cannot recieve vaccine or are high risk (liver disease) |
|||
**Rabies |
|||
**Tetanus |
|||
*'''Active''' immunization refers to a vaccine intended to provoke an immune response and therefore confer protection |
|||
==Components== |
|||
* '''Passive''' immunization refers to the transfer of antibodies to confer protection |
|||
** Mother-to-child transfer and immunoglobulins are examples |
|||
** Hepatitis B |
|||
** Chicken pox, that cannot recieve vaccine (in pregnant women, immunocompromised, baby exposed by mom at birth) |
|||
** Measles, that cannot recieve vaccine |
|||
** Hepatitis A, that cannot recieve vaccine or are high risk (liver disease) |
|||
** Rabies |
|||
** Tetanus |
|||
* '''Active''' immunization refers to a vaccine intended to provoke an immune response and therefore confer protection |
|||
*Immunogen |
|||
== Components == |
|||
**'''Live attenuated:''' a weakened version of a pathogen that provokes an immune response without causing disease |
|||
**'''Inactivated:''' killed pathogens, often provoking a weaker immune response than live, and may have problems with injection of unwanted proteins |
|||
**'''Subunit:''' include proteins, polysaccharides and protein-polysaccharide conjugates |
|||
***Polysaccharide antigens aren't particularly immunogenic |
|||
***Conjugating polysaccharides to proteins generates a more robust memory response |
|||
*'''Adjuvant''' |
|||
**Additional compound that stimulates immune response |
|||
**Canada only uses aluminum salts (aluminum hydroxide, aluminum phosphate or potassium aluminum sulfate) |
|||
***Rare side effects include subcutaneous nodules, granulomatous inflammation or contact hypersensitivity |
|||
*Preservatives |
|||
**Prevent the vaccine from being contaminated with bacteria |
|||
**Includes thimerosal, phenol, and 2-phenoxyethanol |
|||
*Additives |
|||
**May contain trace amount of substances required during the purification process or to confirm vaccine quality |
|||
==List of Vaccines== |
|||
* Immunogen |
|||
** '''Live attenuated:''' a weakened version of a pathogen that provokes an immune response without causing disease |
|||
** '''Inactivated:''' killed pathogens, often provoking a weaker immune response than live, and may have problems with injection of unwanted proteins |
|||
** '''Subunit:''' include proteins, polysaccharides and protein-polysaccharide conjugates |
|||
* Adjuvant |
|||
** Additional compound that stimulates immune response |
|||
** Canada only uses aluminum salts (aluminum hydroxide, aluminum phosphate or potassium aluminum sulfate) |
|||
*** Rare side effects include subcutaneous nodules, granulomatous inflammation or contact hypersensitivity |
|||
* Preservatives |
|||
** Prevent the vaccine from being contaminated with bacteria |
|||
** Includes thimerosal, phenol, and 2-phenoxyethanol |
|||
* Additives |
|||
** May contain trace amount of substances required during the purification process or to confirm vaccine quality |
|||
{| class="wikitable" |
|||
== List of Vaccines == |
|||
!Vaccine |
|||
!Notes |
|||
{| |
|||
! Vaccine |
|||
! Notes |
|||
|- |
|- |
||
| |
|Bacille Calmette-GuΓ©rin Vaccine |
||
| |
| |
||
|- |
|- |
||
| |
|Cholera and Enterotoxigenic Escherichia Coli |
||
| |
| |
||
|- |
|- |
||
| |
|Diphtheria Toxoid |
||
| |
| |
||
|- |
|- |
||
| |
|Haemophilus Influenzae Type B Vaccine |
||
| |
| |
||
|- |
|- |
||
| |
|Hepatitis A Vaccine |
||
| |
| |
||
|- |
|- |
||
| |
|Hepatitis B Vaccine |
||
| |
| |
||
|- |
|- |
||
| |
|Herpes Zoster (Shingles) Vaccine |
||
| |
| |
||
|- |
|- |
||
| |
|Human Papillomavirus Vaccine |
||
| |
| |
||
|- |
|- |
||
| |
|Influenza Vaccine |
||
| |
| |
||
|- |
|- |
||
| |
|Japanese Encephalitis Vaccine |
||
| |
| |
||
|- |
|- |
||
| |
|Measles Vaccine |
||
| |
| |
||
|- |
|- |
||
| |
|Meningococcal Vaccine |
||
| |
| |
||
|- |
|- |
||
| |
|Mumps Vaccine |
||
| |
| |
||
|- |
|- |
||
| |
|Pertussis Vaccine |
||
| |
| |
||
|- |
|- |
||
| |
|Pneumococcal Vaccine |
||
| |
| |
||
|- |
|- |
||
| |
|Poliomyelitis Vaccine |
||
| |
| |
||
|- |
|- |
||
| |
|Rabies Vaccine |
||
| |
| |
||
|- |
|- |
||
| |
|Rotavirus Vaccine |
||
| |
| |
||
|- |
|- |
||
| |
|Rubella Vaccine |
||
| |
| |
||
|- |
|- |
||
| |
|Smallpox Vaccine |
||
| |
| |
||
|- |
|- |
||
| |
|Tetanus Toxoid |
||
| |
| |
||
|- |
|- |
||
| |
|Typhoid Vaccine |
||
| |
|Toxoid vaccine. |
||
|- |
|- |
||
| |
|Varicella (Chickenpox) Vaccine |
||
| |
| |
||
|- |
|- |
||
| |
|Yellow Fever Vaccine |
||
| |
| |
||
|} |
|} |
||
* |
*Live attenuated |
||
** |
**MMR |
||
** |
**Varicella (Zostavax) |
||
** |
**Smallpox |
||
** |
**Oral polio |
||
** |
**Nasal spray influenza |
||
* |
*Killed |
||
** |
**Hep A |
||
** |
**Injectable influenza |
||
** |
**Injectable polio |
||
** |
**Rabies |
||
* |
*Subunit |
||
** |
**Hib |
||
** |
**Hep B |
||
** |
**HPV |
||
** |
**Pertussis, TdAP |
||
** |
**Varicella (Shingrix) |
||
==Pathophysiology== |
|||
*Depends on the specific vaccine |
|||
*Generally work by inducing specific IgG serum antibodies |
|||
**BCG is the only T-cell-specific vaccine, although T-cell response may contribute to others |
|||
*Generally do not elicit a mucosal antibody response, so infection may only be stopped after already infecting a mucosal surface |
|||
**Therefore, they do not induce sterilizing immunity |
|||
*Antigen-presenting cells are activated by a pathogen and in turn stimulate B and T cell response in the local lymph node |
|||
**Live vaccines may travel throughout the body, activating multiple lymph nodes in different sites |
|||
**Non-live vaccines only activate APCs that travel to the local lymph node, explaining why they may be given in multiple limbs at once |
|||
*Protein antigens trigger T-cells to help to activate B-cells in germinal centres |
|||
**It can take a few weeks to produce IgG antibodies |
|||
**IgG peaks within 4-6 weeks of primary immunization |
|||
*Polysaccharide antigens travel to lymphoid tissue where they bind B cells directly and trigger maturation into plasma cells |
|||
**Without germinal centres, memory B cells are not produced |
|||
**Need to be coupled to a carrier protein in order to generate a memory response |
|||
*Memory B cells require several days to redifferentiate into plasma cells upon reexposure |
|||
===T-cells=== |
|||
*Th1: IFN-gamma and TNF-alpha to activate response against intracellular pathogens |
|||
*Th2: IL-4, IL-5, and IL-13 to activate response against extracellular pathogens such as helminths |
|||
==Vaccination Schedule== |
|||
*[https://www.canada.ca/en/public-health/services/provincial-territorial-immunization-information/provincial-territorial-routine-vaccination-programs-infants-children.html Canada's Provincial and Territorial Routine (and Catch-up) Vaccination Routine Schedule Programs for Infants and Children] |
|||
*[https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-1-key-immunization-information/page-13-recommended-immunization-schedules.html Canadian Immunization Guide: Recommended Immunization Schedules] |
|||
*[https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-3-vaccination-specific-populations/page-10-immunization-persons-new-canada.html Canadian Immunization Guide: Immunization of Persons New to Canada] |
|||
===Adult Vaccination=== |
|||
====Pneumococcus==== |
|||
*Conjugate better than polysaccharide |
|||
**Prevnar: PC-7, then PC-10 and PC-13 |
|||
***Conjugated with diphtheria CRM197 |
|||
***Incremental benefit of vaccinating adults over and above vaccinating children is not high enough to warrant funding the vaccine |
|||
**Pneumovax: PS-23 |
|||
*In age >65 years or other high-risk groups, PC first, then PS 8 weeks later (recommended), though only PS is paid for in Ontario |
|||
*For high-risk groups, add a PS booster at 5 years |
|||
*If PS-23 already given, wait a year before giving PC-13 |
|||
====Influenza==== |
|||
*Trivalent has H1N1 and H2N3 (both flu A) and a flu B strain |
|||
== Pathophysiology == |
|||
*The quadrivalent adds a second flu B, for children who get more flu B |
|||
**The first time someone receives the vaccine, they need a second booster |
|||
*The high dose is more effective but more expensive (Fluzone) |
|||
**Trivalent vaccine |
|||
**24% increase in efficacy in the elderly (brings up to normal population) |
|||
*Ensure that higher risk patients are vaccinated as well as their household |
|||
====Shingles/Varicella-zoster==== |
|||
* Depends on the specific vaccine |
|||
* Generally work by inducing specific IgG serum antibodies |
|||
** BCG is the only T-cell-specific vaccine, although T-cell response may contribute to others |
|||
* Generally do not elicit a mucosal antibody response, so infection may only be stopped after already infecting a mucosal surface |
|||
** Therefore, they do not induce sterilizing immunity |
|||
* Antigen-presenting cells are activated by a pathogen and in turn stimulate B and T cell response in the local lymph node |
|||
** Live vaccines may travel throughout the body, activating multiple lymph nodes in different sites |
|||
** Non-live vaccines only activate APCs that travel to the local lymph node, explaining why they may be given in multiple limbs at once |
|||
* Protein antigens trigger T-cells to help to activate B-cells in germinal centres |
|||
** It can take a few weeks to produce IgG antibodies |
|||
** IgG peaks within 4-6 weeks of primary immunization |
|||
* Polysaccharide antigens travel to lymphoid tissue where they bind B cells directly and trigger maturation into plasma cells |
|||
** Without germinal centres, memory B cells are not produced |
|||
** Need to be coupled to a carrier protein in order to generate a memory response |
|||
* Memory B cells require several days to redifferentiate into plasma cells upon reexposure |
|||
*Live attenuated zoster vaccine (Zostavax) |
|||
=== T-cells === |
|||
**Can be given if pred <20 mg/d or <14 days, low-dose methotrexate, azathioprine, 6MP, hydroxychloroquine, sulfasalazine, etc. |
|||
*Recombinatnt glycoprotein vaccine (Shingrix), 2 doses IM 2 months apart |
|||
**Protection is at least 3-4 years, possibly longer |
|||
====Asplenia==== |
|||
* Th1: IFN-gamma and TNF-alpha to activate response against intracellular pathogens |
|||
* Th2: IL-4, IL-5, and IL-13 to activate response against extracellular pathogens such as helminths |
|||
*Risk factor for encapsulated organisms: ''[[Streptococcus pneumoniae]]'', ''[[Haemophilus influenzae]]'' type B, and ''[[Neisseria meningitidis]]'' |
|||
== Vaccination Schedule == |
|||
*Splenectomy, indications include trauma, cancer, [[ITP]] |
|||
*Also beware functional asplenia as in [[sickle cell disease]] and Howell-Jolly bodies |
|||
*Highest risk in the first 5 years, but can be up to 20 years out |
|||
*2 weeks before elective or 2 weeks after unplanned emergent |
|||
*Recommended vaccines |
|||
**Menactra (conjugate ACYW-135) + Bexsero (Men B, but not covered) |
|||
***Second dose at 8 weeks, or later if given after splenectomy |
|||
**HiB once |
|||
**Pill-in-pocket amox/clav or levoflox to take on the way to ED if they get a fever |
|||
*Travel precautions: be careful about babesia in New England (fulminant sepsis and die), as well as malaria |
|||
*Dog bites are very high risk for severe ''Capnocytophaga'' |
|||
**Prophylaxis with amox/clav x5 days |
|||
===Close Contacts of Immunocompromised Patients=== |
|||
* [https://www.canada.ca/en/public-health/services/provincial-territorial-immunization-information/provincial-territorial-routine-vaccination-programs-infants-children.html Canada's Provincial and Territorial Routine (and Catch-up) Vaccination Routine Schedule Programs for Infants and Children] |
|||
* [https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-1-key-immunization-information/page-13-recommended-immunization-schedules.html Canadian Immunization Guide: Recommended Immunization Schedules] |
|||
* [https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-3-vaccination-specific-populations/page-10-immunization-persons-new-canada.html Canadian Immunization Guide: Immunization of Persons New to Canada] |
|||
*In general, close contacts should receive all routine vaccines, including rotavirus and annual influenza |
|||
=== Adult Vaccination === |
|||
*Specific vaccines do have some caveats, however: |
|||
**[[Rotavirus]]: the immunocompromised patient should not change diapers for 4 weeks after the infant receives their vaccine |
|||
**[[Varicella-zoster virus]] (live): avoid contact only if the vaccinated household member develops a rash (rare) |
|||
**[[Influenza]] (live, annual): avoid close contact for 2 weeks after the household member receives their vaccine |
|||
**[[Poliovirus]] (live, oral): do ''not'' immunize close contacts with the live oral polio vaccine |
|||
**[[Smallpox]]: avoid vaccinating close contacts if at all possible |
|||
*Of note, the strains in the MMR vaccine are not transmitted person-to-person, so it is safe for close contacts to be vaccinated with MMR |
|||
=== |
===Catch-Up Immunization=== |
||
====Starting Between 1 and 6 Years==== |
|||
* Conjugate better than polysaccharide |
|||
** Prevnar: PC-7, then PC-10 and PC-13 |
|||
*** Conjugated with diphtheria CRM197 |
|||
*** Incremental benefit of vaccinating adults over and above vaccinating children is not high enough to warrant funding the vaccine |
|||
** Pneumovax: PS-23 |
|||
* In age >65 years or other high-risk groups, PC first, then PS 8 weeks later (recommended), though only PS is paid for in Ontario |
|||
* For high-risk groups, add a PS booster at 5 years |
|||
* If PS-23 already given, wait a year before giving PC-13 |
|||
*First visit: |
|||
==== Influenza ==== |
|||
**<4 years: DTaP-IPV-Hib, Pneu-C-13, MMR, Men-C-C |
|||
**4 years: DTaP-IPV-Hib, Pneu-C-13, MMRV, Men-C-C |
|||
**5-6 years: MMRV, DTaP-IPV, Men-C-C |
|||
*Second visit, at 2 months |
|||
**If child is <5 years at was: |
|||
***<15 months at first visit: DTaP=IPV-Hib, Pneu-C-13, Var |
|||
***15-23 months at first visit: Pneu-C-13, DTaP-IPV, Var |
|||
***2-3 years at first visit: DTaP-IPV, Var |
|||
***4 years at first visitDTaP-IPV |
|||
**5-6 years: DTaP-IPV |
|||
**7 years: Tdap-IPV |
|||
*Third visit, 2 months after second visit |
|||
**<7 years: DTaP-IPV |
|||
**7 years: Tdap |
|||
*Fourth visit, 6-12 months after third visit |
|||
**<4 years: DTaP-IPV |
|||
**4-8 years: MMRV, Tdap-IPV |
|||
*Fifth visit, 6-12 months after fourth visit and 4-6 years of age, only if child was <4 years at fourth visit |
|||
**MMRV, Tdap-IPV |
|||
*Grade 7: HB, Men-C-ACYW, HPV-4 |
|||
*14-16 years: Tdap |
|||
*24-36 years: Tdap |
|||
*β₯34 years: Td every 10 years |
|||
*65 years: HZ, Pneu-P-23 |
|||
====Starting Between 7 and 17 years==== |
|||
* Trivalent has H1N1 and H2N3 (both flu A) and a flu B strain |
|||
* The quadrivalent adds a second flu B, for children who get more flu B |
|||
** The first time someone receives the vaccine, they need a second booster |
|||
* The high dose is more effective but more expensive (Fluzone) |
|||
** Trivalent vaccine |
|||
** 24% increase in efficacy in the elderly (brings up to normal population) |
|||
* Ensure that higher risk patients are vaccinated as well as their household |
|||
*First visit |
|||
==== Shingles/Varicella zoster ==== |
|||
**<13 years: Tdap-IPV, MMRV, Men-C-C |
|||
**β₯13 years: Tdap-IPV, MMR, Var |
|||
*Second visit, 2 months after first visit |
|||
**<13 years: Tdap-IPV, MMRV |
|||
**β₯13 years: Tdap-IPV, MMR, Var |
|||
*Third visit, 6-12 months after second visit |
|||
**Tdap-IPV |
|||
*Fourth visit, 10 years after third visit and only if child was <18 years at third visit |
|||
**Tdap |
|||
*Grade 7: HPV-4 |
|||
*Grade 7 or 8: HB |
|||
*Grade 7-12: Men-C-ACYW |
|||
*Grade 8-12: HPV-4 |
|||
*Every ten years: Td |
|||
*65 years: Pneu-P-23 |
|||
====Starting at 18 Years and Older==== |
|||
* Live attenuated zoster vaccine (Zostavax) |
|||
** Can be given if pred <20 mg/d or <14 days, low-dose methotrexate, azathioprine, 6MP, hydroxychloroquine, sulfasalazine, etc. |
|||
* Recombinatnt glycoprotein vaccine (Shingrix), 2 doses IM 2 months apart |
|||
** Protection is at least 3-4 years, possibly longer |
|||
*First visit |
|||
==== Asplenia ==== |
|||
**Born before 1985: Tdap-IPV, MMR |
|||
**Born between 1986 and 1996: Tdap-IPV, MMR, Men-C-C |
|||
**Born in or after 1997: Tdap-IPV, MMR, Men-C-ACYW |
|||
*Second visit, 2 months after first visit |
|||
**18-25 years: MMR, Td-IPV |
|||
**β₯26 years: Td-IPV |
|||
*Third visit, 6 to 12 months after second visit: Td-IPV |
|||
*Every 10 years: Td |
|||
*65 years: Pneu-P-23 |
|||
==Contraindications== |
|||
* Risk factor for encapsulated organisms: ''Streptococcus pneumoniae'', ''Haemophilus influenzae'' type B, and ''Neisseria meningitidis'' |
|||
* Splenectomy, indications include trauma, cancer, ITP |
|||
* Also beware functional asplenia as in sickle cell disease and Howell-Jolly bodies |
|||
* Highest risk in the first 5 years, but can be up to 20 years out |
|||
* 2 weeks before elective or 2 weeks after unplanned emergent |
|||
* Recommended vaccines |
|||
** Menactra (conjugate ACYW-135) + Bexsero (Men B, but not covered) |
|||
*** Second dose at 8 weeks, or later if given after splenectomy |
|||
** HiB once |
|||
** Pill-in-pocket amox/clav or levoflox to take on the way to ED if they get a fever |
|||
* Travel precautions: be careful about babesia in New England (fulminant sepsis and die), as well as malaria |
|||
* Dog bites are very high risk for severe ''Capnocytophaga'' |
|||
** Prophylaxis with amox/clav x5 days |
|||
*[[Anaphylaxis]] to the vaccine or a component of the vaccine |
|||
== Contraindications == |
|||
*[[Guillain-BarrΓ© syndrome|GBS]] within 6 weeks of immunization not attributable to other cause |
|||
*Usually deferred in cases of: |
|||
**Current or recent acute febrile illness |
|||
**Immunosuppressive therapy |
|||
***Includes [[Prednisone]] β₯20 mg and duration >14 days |
|||
***Generally wait at least 4 weeks following high-dose steroids, or up to 6-12 months or more for rituximab and some other biological response modifiers |
|||
***For inactivated vaccines, wait 3 months after immunosuppression stops (since they're less immunogenic) |
|||
**[[Pregnancy]] (live vaccines) |
|||
*Live vaccines |
|||
**Immunocompromised |
|||
**Suspicious family or personal history of [[Primary immunodeficiency|immunodeficiency]] |
|||
**[[Pregnancy]] (as a precaution) |
|||
**Live influenza: severe [[asthma]] |
|||
*[[Rotavirus]]: congenital GI malformation or history of [[intussusception]] |
|||
*MMR/MMRV/VZV/HZV: active, untreated [[tuberculosis]] |
|||
*BCG or yellow fever: infant with signs and symptoms of [[AIDS]] |
|||
===Acute Illness=== |
|||
* Anaphylaxis to the vaccine or a component of the vaccine |
|||
* GBS within 6 weeks of immunization not attributable to other cause |
|||
* Usually deferred in cases of |
|||
** Acute febrile illness |
|||
** Immunosuppressive therapy |
|||
*** Prednisone β₯20 mg and duration >14 days |
|||
*** Inactivated given 3 mo after immunosuppression stops (since they're less immunogenic) |
|||
*** Live given 1-3 mo after immunosuppression stops |
|||
** Pregnancy (live vaccines) |
|||
* Live vaccines |
|||
** Immunocompromised |
|||
** Suspicious family or personal history of immunodeficiency |
|||
** Pregnancy (as a precaution) |
|||
** Live influenza: severe asthma |
|||
* Rotavirus: congenital GI malformation or history of intussusception |
|||
* MMR/MMRV/VZV/HZV: active, untreated tuberculosis |
|||
* BCG or yellow fever: infant with signs and symptoms of AIDS |
|||
*If significant nasal congestion is present that might impede delivery of LAIV to the nasopharyngeal mucosa, TIV can be administered or LAIV could be deferred until resolution of the illness. |
|||
=== Acute illness === |
|||
*In infants with moderate-to-severe gastroenteritis, rotavirus vaccine should be deferred until the condition improves unless deferral will result in scheduling of the first dose beyond the recommended age limit. |
|||
*Administration of oral cholera and travellers' diarrhea vaccine should be postponed in persons with acute gastrointestinal illness. |
|||
====IVIg and Transfusion==== |
|||
* If significant nasal congestion is present that might impede delivery of LAIV to the nasopharyngeal mucosa, TIV can be administered or LAIV could be deferred until resolution of the illness. |
|||
* In infants with moderate-to-severe gastroenteritis, rotavirus vaccine should be deferred until the condition improves unless deferral will result in scheduling of the first dose beyond the recommended age limit. |
|||
* Administration of oral cholera and travellers' diarrhea vaccine should be postponed in persons with acute gastrointestinal illness. |
|||
*IVIg at 2 g/kg, wait 11 months before giving live vaccines |
|||
==== IVIg and Transfusion ==== |
|||
*Even pRBC, should wait 4-5 months |
|||
==Side Effects== |
|||
* IVIg at 2 g/kg, wait 11 months before giving live vaccines |
|||
* Even pRBC, should wait 4-5 months |
|||
*Common to very common [[Adverse event following immunization|AEFI]] |
|||
== Side Effects == |
|||
**Vaccination site pain and swelling |
|||
**Fever |
|||
**Fever/rash a week after MMR |
|||
**Large local reactions |
|||
***Giant red swollen injection site or arm (not [[cellulitis]], just watch and wait) |
|||
***Commonly recur, especially tetanus-containing vaccines |
|||
*Uncommon AEFI |
|||
**Hypotonic-hyporesponsive events (HHE) after infant vaccines (especially pertussis-containing vaccines) |
|||
**Lymphadenopathy (MMR) |
|||
*Rare AEFI |
|||
**Febrile seizure after MMR vaccine |
|||
*Very rare AEFI |
|||
**Anaphylaxis after any vaccine |
|||
**BCG can cause all sorts of things: lymphadenopathy, abscesses, disseminated |
|||
==Vaccine Hesitancy== |
|||
* Common to very common AEFI |
|||
** Vaccination site pain and swelling |
|||
** Fever |
|||
** Fever/rash a week after MMR |
|||
** Large local reactions |
|||
*** Giant red swollen injection site or arm (not cellulitis, just watch and wait) |
|||
*** Commonly recur, especially tetanus-containing vaccines |
|||
* Uncommon AEFI |
|||
** Hypotonic-hyporesponsive events (HHE) after infant vaccines (especially pertussis-containing vaccines) |
|||
** Lymphadenopathy (MMR) |
|||
* Rare AEFI |
|||
** Febrile seizure after MMR vaccine |
|||
* Very rare AEFI |
|||
** Anaphylaxis after any vaccine |
|||
** BCG can cause all sorts of things: lymphadenopathy, abscesses, disseminated |
|||
*Stay engaged with the patient/parent |
|||
== Vaccine Hesitancy == |
|||
*Use presumptive language (e.g. "it's time to give you your immunizations today") |
|||
*Use motivational interviewing |
|||
**Open-ended question about specific question |
|||
**Affirmation |
|||
**Reflective listening |
|||
*Use clear language to present risks and benefits fairly |
|||
**Use framing: "If you decide not to get the HPV vaccine, you increase your risk of getting HPV and cervical cancer" (instead of getting it decreases your risk); "the vaccine is 99% safe" (instead of 1% risk) |
|||
*Address pain and fear of pain (for children) |
|||
*Emphasize that herd immunity is not a guarantee, especially if there is an outbreak |
|||
===Further Reading=== |
|||
* Stay engaged with the patient/parent |
|||
* Use presumptive language (e.g. "it's time to give you your immunizations today") |
|||
* Use motivational interviewing |
|||
** Open-ended question about specific question |
|||
** Affirmation |
|||
** Reflective listening |
|||
* Use clear language to present risks and benefits fairly |
|||
** Use framing: "If you decide not to get the HPV vaccine, you increase your risk of getting HPV and cervical cancer" (instead of getting it decreases your risk); "the vaccine is 99% safe" (instead of 1% risk) |
|||
* Address pain and fear of pain (for children) |
|||
* Emphasize that herd immunity is not a guarantee, especially if there is an outbreak |
|||
*WHO: [http://www.who.int/vaccine_safety/initiative/detection/immunization_misconceptions/en/ Six common misconceptions about immunization] |
|||
=== Further Reading === |
|||
*CPS: [https://www.cps.ca/en/documents/position/working-with-vaccine-hesitant-parents Working with vaccine-hesitant parents: An update] |
|||
==Further Reading== |
|||
* WHO: [http://www.who.int/vaccine_safety/initiative/detection/immunization_misconceptions/en/ Six common misconceptions about immunization] |
|||
* CPS: [https://www.cps.ca/en/documents/position/working-with-vaccine-hesitant-parents Working with vaccine-hesitant parents: An update] |
|||
*[https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-2-vaccine-safety/page-3-contraindications-precautions-concerns.html Canadian Immunization Guide: Contraindications, Precautions and Concerns] |
|||
== Further Reading == |
|||
[[Category:Vaccination]] |
|||
* [https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-2-vaccine-safety/page-3-contraindications-precautions-concerns.html Canadian Immunization Guide: Contraindications, Precautions and Concerns] |
Latest revision as of 15:25, 10 December 2020
Passive and Active
- Passive immunization refers to the transfer of antibodies to confer protection
- Mother-to-child transfer and immunoglobulins are examples
- Hepatitis B
- Chicken pox, that cannot recieve vaccine (in pregnant women, immunocompromised, baby exposed by mom at birth)
- Measles, that cannot recieve vaccine
- Hepatitis A, that cannot recieve vaccine or are high risk (liver disease)
- Rabies
- Tetanus
- Active immunization refers to a vaccine intended to provoke an immune response and therefore confer protection
Components
- Immunogen
- Live attenuated: a weakened version of a pathogen that provokes an immune response without causing disease
- Inactivated: killed pathogens, often provoking a weaker immune response than live, and may have problems with injection of unwanted proteins
- Subunit: include proteins, polysaccharides and protein-polysaccharide conjugates
- Polysaccharide antigens aren't particularly immunogenic
- Conjugating polysaccharides to proteins generates a more robust memory response
- Adjuvant
- Additional compound that stimulates immune response
- Canada only uses aluminum salts (aluminum hydroxide, aluminum phosphate or potassium aluminum sulfate)
- Rare side effects include subcutaneous nodules, granulomatous inflammation or contact hypersensitivity
- Preservatives
- Prevent the vaccine from being contaminated with bacteria
- Includes thimerosal, phenol, and 2-phenoxyethanol
- Additives
- May contain trace amount of substances required during the purification process or to confirm vaccine quality
List of Vaccines
Vaccine | Notes |
---|---|
Bacille Calmette-GuΓ©rin Vaccine | |
Cholera and Enterotoxigenic Escherichia Coli | |
Diphtheria Toxoid | |
Haemophilus Influenzae Type B Vaccine | |
Hepatitis A Vaccine | |
Hepatitis B Vaccine | |
Herpes Zoster (Shingles) Vaccine | |
Human Papillomavirus Vaccine | |
Influenza Vaccine | |
Japanese Encephalitis Vaccine | |
Measles Vaccine | |
Meningococcal Vaccine | |
Mumps Vaccine | |
Pertussis Vaccine | |
Pneumococcal Vaccine | |
Poliomyelitis Vaccine | |
Rabies Vaccine | |
Rotavirus Vaccine | |
Rubella Vaccine | |
Smallpox Vaccine | |
Tetanus Toxoid | |
Typhoid Vaccine | Toxoid vaccine. |
Varicella (Chickenpox) Vaccine | |
Yellow Fever Vaccine |
- Live attenuated
- MMR
- Varicella (Zostavax)
- Smallpox
- Oral polio
- Nasal spray influenza
- Killed
- Hep A
- Injectable influenza
- Injectable polio
- Rabies
- Subunit
- Hib
- Hep B
- HPV
- Pertussis, TdAP
- Varicella (Shingrix)
Pathophysiology
- Depends on the specific vaccine
- Generally work by inducing specific IgG serum antibodies
- BCG is the only T-cell-specific vaccine, although T-cell response may contribute to others
- Generally do not elicit a mucosal antibody response, so infection may only be stopped after already infecting a mucosal surface
- Therefore, they do not induce sterilizing immunity
- Antigen-presenting cells are activated by a pathogen and in turn stimulate B and T cell response in the local lymph node
- Live vaccines may travel throughout the body, activating multiple lymph nodes in different sites
- Non-live vaccines only activate APCs that travel to the local lymph node, explaining why they may be given in multiple limbs at once
- Protein antigens trigger T-cells to help to activate B-cells in germinal centres
- It can take a few weeks to produce IgG antibodies
- IgG peaks within 4-6 weeks of primary immunization
- Polysaccharide antigens travel to lymphoid tissue where they bind B cells directly and trigger maturation into plasma cells
- Without germinal centres, memory B cells are not produced
- Need to be coupled to a carrier protein in order to generate a memory response
- Memory B cells require several days to redifferentiate into plasma cells upon reexposure
T-cells
- Th1: IFN-gamma and TNF-alpha to activate response against intracellular pathogens
- Th2: IL-4, IL-5, and IL-13 to activate response against extracellular pathogens such as helminths
Vaccination Schedule
- Canada's Provincial and Territorial Routine (and Catch-up) Vaccination Routine Schedule Programs for Infants and Children
- Canadian Immunization Guide: Recommended Immunization Schedules
- Canadian Immunization Guide: Immunization of Persons New to Canada
Adult Vaccination
Pneumococcus
- Conjugate better than polysaccharide
- Prevnar: PC-7, then PC-10 and PC-13
- Conjugated with diphtheria CRM197
- Incremental benefit of vaccinating adults over and above vaccinating children is not high enough to warrant funding the vaccine
- Pneumovax: PS-23
- Prevnar: PC-7, then PC-10 and PC-13
- In age >65 years or other high-risk groups, PC first, then PS 8 weeks later (recommended), though only PS is paid for in Ontario
- For high-risk groups, add a PS booster at 5 years
- If PS-23 already given, wait a year before giving PC-13
Influenza
- Trivalent has H1N1 and H2N3 (both flu A) and a flu B strain
- The quadrivalent adds a second flu B, for children who get more flu B
- The first time someone receives the vaccine, they need a second booster
- The high dose is more effective but more expensive (Fluzone)
- Trivalent vaccine
- 24% increase in efficacy in the elderly (brings up to normal population)
- Ensure that higher risk patients are vaccinated as well as their household
Shingles/Varicella-zoster
- Live attenuated zoster vaccine (Zostavax)
- Can be given if pred <20 mg/d or <14 days, low-dose methotrexate, azathioprine, 6MP, hydroxychloroquine, sulfasalazine, etc.
- Recombinatnt glycoprotein vaccine (Shingrix), 2 doses IM 2 months apart
- Protection is at least 3-4 years, possibly longer
Asplenia
- Risk factor for encapsulated organisms: Streptococcus pneumoniae, Haemophilus influenzae type B, and Neisseria meningitidis
- Splenectomy, indications include trauma, cancer, ITP
- Also beware functional asplenia as in sickle cell disease and Howell-Jolly bodies
- Highest risk in the first 5 years, but can be up to 20 years out
- 2 weeks before elective or 2 weeks after unplanned emergent
- Recommended vaccines
- Menactra (conjugate ACYW-135) + Bexsero (Men B, but not covered)
- Second dose at 8 weeks, or later if given after splenectomy
- HiB once
- Pill-in-pocket amox/clav or levoflox to take on the way to ED if they get a fever
- Menactra (conjugate ACYW-135) + Bexsero (Men B, but not covered)
- Travel precautions: be careful about babesia in New England (fulminant sepsis and die), as well as malaria
- Dog bites are very high risk for severe Capnocytophaga
- Prophylaxis with amox/clav x5 days
Close Contacts of Immunocompromised Patients
- In general, close contacts should receive all routine vaccines, including rotavirus and annual influenza
- Specific vaccines do have some caveats, however:
- Rotavirus: the immunocompromised patient should not change diapers for 4 weeks after the infant receives their vaccine
- Varicella-zoster virus (live): avoid contact only if the vaccinated household member develops a rash (rare)
- Influenza (live, annual): avoid close contact for 2 weeks after the household member receives their vaccine
- Poliovirus (live, oral): do not immunize close contacts with the live oral polio vaccine
- Smallpox: avoid vaccinating close contacts if at all possible
- Of note, the strains in the MMR vaccine are not transmitted person-to-person, so it is safe for close contacts to be vaccinated with MMR
Catch-Up Immunization
Starting Between 1 and 6 Years
- First visit:
- <4 years: DTaP-IPV-Hib, Pneu-C-13, MMR, Men-C-C
- 4 years: DTaP-IPV-Hib, Pneu-C-13, MMRV, Men-C-C
- 5-6 years: MMRV, DTaP-IPV, Men-C-C
- Second visit, at 2 months
- If child is <5 years at was:
- <15 months at first visit: DTaP=IPV-Hib, Pneu-C-13, Var
- 15-23 months at first visit: Pneu-C-13, DTaP-IPV, Var
- 2-3 years at first visit: DTaP-IPV, Var
- 4 years at first visitDTaP-IPV
- 5-6 years: DTaP-IPV
- 7 years: Tdap-IPV
- If child is <5 years at was:
- Third visit, 2 months after second visit
- <7 years: DTaP-IPV
- 7 years: Tdap
- Fourth visit, 6-12 months after third visit
- <4 years: DTaP-IPV
- 4-8 years: MMRV, Tdap-IPV
- Fifth visit, 6-12 months after fourth visit and 4-6 years of age, only if child was <4 years at fourth visit
- MMRV, Tdap-IPV
- Grade 7: HB, Men-C-ACYW, HPV-4
- 14-16 years: Tdap
- 24-36 years: Tdap
- β₯34 years: Td every 10 years
- 65 years: HZ, Pneu-P-23
Starting Between 7 and 17 years
- First visit
- <13 years: Tdap-IPV, MMRV, Men-C-C
- β₯13 years: Tdap-IPV, MMR, Var
- Second visit, 2 months after first visit
- <13 years: Tdap-IPV, MMRV
- β₯13 years: Tdap-IPV, MMR, Var
- Third visit, 6-12 months after second visit
- Tdap-IPV
- Fourth visit, 10 years after third visit and only if child was <18 years at third visit
- Tdap
- Grade 7: HPV-4
- Grade 7 or 8: HB
- Grade 7-12: Men-C-ACYW
- Grade 8-12: HPV-4
- Every ten years: Td
- 65 years: Pneu-P-23
Starting at 18 Years and Older
- First visit
- Born before 1985: Tdap-IPV, MMR
- Born between 1986 and 1996: Tdap-IPV, MMR, Men-C-C
- Born in or after 1997: Tdap-IPV, MMR, Men-C-ACYW
- Second visit, 2 months after first visit
- 18-25 years: MMR, Td-IPV
- β₯26 years: Td-IPV
- Third visit, 6 to 12 months after second visit: Td-IPV
- Every 10 years: Td
- 65 years: Pneu-P-23
Contraindications
- Anaphylaxis to the vaccine or a component of the vaccine
- GBS within 6 weeks of immunization not attributable to other cause
- Usually deferred in cases of:
- Current or recent acute febrile illness
- Immunosuppressive therapy
- Includes Prednisone β₯20 mg and duration >14 days
- Generally wait at least 4 weeks following high-dose steroids, or up to 6-12 months or more for rituximab and some other biological response modifiers
- For inactivated vaccines, wait 3 months after immunosuppression stops (since they're less immunogenic)
- Pregnancy (live vaccines)
- Live vaccines
- Immunocompromised
- Suspicious family or personal history of immunodeficiency
- Pregnancy (as a precaution)
- Live influenza: severe asthma
- Rotavirus: congenital GI malformation or history of intussusception
- MMR/MMRV/VZV/HZV: active, untreated tuberculosis
- BCG or yellow fever: infant with signs and symptoms of AIDS
Acute Illness
- If significant nasal congestion is present that might impede delivery of LAIV to the nasopharyngeal mucosa, TIV can be administered or LAIV could be deferred until resolution of the illness.
- In infants with moderate-to-severe gastroenteritis, rotavirus vaccine should be deferred until the condition improves unless deferral will result in scheduling of the first dose beyond the recommended age limit.
- Administration of oral cholera and travellers' diarrhea vaccine should be postponed in persons with acute gastrointestinal illness.
IVIg and Transfusion
- IVIg at 2 g/kg, wait 11 months before giving live vaccines
- Even pRBC, should wait 4-5 months
Side Effects
- Common to very common AEFI
- Vaccination site pain and swelling
- Fever
- Fever/rash a week after MMR
- Large local reactions
- Giant red swollen injection site or arm (not cellulitis, just watch and wait)
- Commonly recur, especially tetanus-containing vaccines
- Uncommon AEFI
- Hypotonic-hyporesponsive events (HHE) after infant vaccines (especially pertussis-containing vaccines)
- Lymphadenopathy (MMR)
- Rare AEFI
- Febrile seizure after MMR vaccine
- Very rare AEFI
- Anaphylaxis after any vaccine
- BCG can cause all sorts of things: lymphadenopathy, abscesses, disseminated
Vaccine Hesitancy
- Stay engaged with the patient/parent
- Use presumptive language (e.g. "it's time to give you your immunizations today")
- Use motivational interviewing
- Open-ended question about specific question
- Affirmation
- Reflective listening
- Use clear language to present risks and benefits fairly
- Use framing: "If you decide not to get the HPV vaccine, you increase your risk of getting HPV and cervical cancer" (instead of getting it decreases your risk); "the vaccine is 99% safe" (instead of 1% risk)
- Address pain and fear of pain (for children)
- Emphasize that herd immunity is not a guarantee, especially if there is an outbreak
Further Reading
- WHO: Six common misconceptions about immunization
- CPS: Working with vaccine-hesitant parents: An update